To amend the Federal Food, Drug, and Cosmetic Act to provide for the development and use of patient experience data to enhance the structured risk-benefit assessment framework, and for other purposes.
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (May 14, 2015)
This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish processes under which: (1) an entity seeking to develop patient experience data may submit initial research concepts for feedback; (2) the FDA may request or receive from such an entity draft guidance documents, data, and summaries and analyses of data; and (3) patient experience data may be considered in the risk-benefit assessment of a new drug.
“Patient experience data” is data collected by patients or others that is intended to facilitate the FDA's risk-benefit assessments, including information about the impact of a disease or a therapy on patients' lives.
The FDA must convene workshops and publish guidance on the patient experience data processes described above.What just happenedMay 15, 2015
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseMay 14, 2015
- May 15, 2015Committee
Referred to the Subcommittee on Health.
Health Subcommittee - May 14, 2015IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - May 14, 2015IntroReferralIntro-H
Introduced in House
- May 14, 2015IntroReferral1000
Introduced in House